COMPANY

Provectus Biopharmaceuticals

HQ: Knoxville, TN source · provectusbio.com ↗

Location: Knoxville, TN · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Melanoma Neuroendocrine Tumors Metastatic to the Liver Cancer Metastatic to the Liver Hepatocellular Carcinoma Metastatic Melanoma Metastatic Ocular Melanoma Metastatic Uveal Melanoma Metastatic Lung Cancer Metastatic Colon Cancer Metastatic Colorectal Cancer Metastatic Breast Cancer Metastatic Pancreatic Cancer Cutaneous Melanoma Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory Approved Alternative Therapy PV-10

5Trials (company is sponsor)

Timeline

2016-07 Trial start 1: A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver source ↗
2015-10 Trial start Phase 1/Phase 2: PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma source ↗
2015-04 Trial start Phase 3: PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma source ↗
2009-10 Trial start Phase 1: A Study to Assess PV-10 Chemoablation of Cancer of the Liver source ↗

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT02557321	PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma	Phase 1/Phase 2	Unknown status (ClinicalTrials.gov)	2015-10	2023-05 (actual)
NCT02693067	A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver	1	Unknown status (ClinicalTrials.gov)	2016-07	Sep 1, 2021 (actual)
NCT00986661	A Study to Assess PV-10 Chemoablation of Cancer of the Liver	Phase 1	Unknown status (ClinicalTrials.gov)	2009-10	2022-12 (estimated)
NCT02288897	PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma	Phase 3	Terminated	2015-04	2019-04 (actual)
NCT01260779	Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors	Not listed	No longer available	Not listed	Not listed